Physician profile
Amy R Epps
NPI 1235247198
$3,266.83
in general payments reported to CMS, 2019-2025
25 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $170 · 2021: $344 · 2022: $754 · 2023: $1,022 · 2024: $185 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,005.56 | 2019-2025 | |
| Medtronic, INC. | $457.74 | 2021-2025 | Onyx Frontier, Micra, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $301.81 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $237.02 | 2020-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $228.67 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $228.07 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Inari Medical, INC. | $169.60 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $113.98 | 2019-2022 | |
| Pfizer INC. | $102.31 | 2019-2025 | |
| Biotronik INC. | $83.82 | 2025 | |
| Novo Nordisk INC | $36.19 | 2019-2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $33.82 | 2019 | |
| Medtronic Vascular, INC. | $33.42 | 2019 | |
| Alnylam Pharmaceuticals INC. | $33.00 | 2025 | Onpattro |
| Astrazeneca Pharmaceuticals Lp | $24.49 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $23.92 | 2022 | |
| Biosense Webster, INC. | $22.86 | 2019 | |
| Penumbra, INC. | $21.91 | 2024 | Indigo System |
| Cordis US Corp. | $19.96 | 2025 | Mynx Control Venous |
| Glaxosmithkline, LLC. | $18.25 | 2024 | Bexsero |
| Atricure, INC. | $16.86 | 2023 | |
| Edwards Lifesciences Corporation | $15.72 | 2025 | |
| Azurity Pharmaceuticals, INC. | $13.90 | 2025 | Edarbyclor |
| Cvrx, INC. | $12.58 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Epps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.